Expression of Cyclin B1 and cdc2 in Nodal Non-Hodgkin's Lymphoma and its Prognostic Implications.
10.3346/jkms.2002.17.3.322
- Author:
Yun Hee JIN
1
;
Chan Kum PARK
Author Information
1. Department of Pathology, College of Medicine, Hanyang University, Seoul, Korea. parkcg@hanyang.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Lymphoma;
Malignant;
Cyclin B1;
cdc2
- MeSH:
Adolescent;
Adult;
Aged;
CDC2 Protein Kinase/*biosynthesis;
Child;
Child, Preschool;
Cyclin B/*biosynthesis;
Cyclin B1;
Female;
Humans;
Immunohistochemistry;
Ki-67 Antigen/biosynthesis;
Lymph Nodes/metabolism/pathology;
*Lymphoma, Non-Hodgkin/metabolism/mortality/pathology;
Male;
Middle Aged;
Palatine Tonsil/metabolism/pathology;
Predictive Value of Tests;
Prognosis;
Survival Analysis;
Tumor Suppressor Protein p53/biosynthesis
- From:Journal of Korean Medical Science
2002;17(3):322-327
- CountryRepublic of Korea
- Language:English
-
Abstract:
To investigate the role of cyclin B1 and cdc2 in the pathogenesis and progression of malignant lymphoma, 68 cases of nodal non-Hodgkin's lymphoma were examined about the expression of cyclin B1 and cdc2 along with p53 and Ki-67 by immunohistochemical method. The correlation of their expression with various clinicopathologic findings was also analyzed. Cyclin B1 and cdc2 were diffusely expressed in 39 cases (57.4%) and 54 cases (79.4%) out of 68 cases studied, respectively. The mean labeling indices of cyclin B1 and cdc2 in malignant lymphoma were 31.9% and 68.0%, respectively. In normal lymphoid tissues, cyclin B1 and cdc2 were expressed predominantly in the germinal center with mean labeling indices of 13.9% and 28.3%, respectively. The correlation between the expression of cyclin B1 and cdc2 was noted (p=0.013). The expression of Ki-67 was correlated with that of cyclin B1 (p=0.023) and marginally correlated with that of cdc2 (p=0.056). The expression of cdc2 and p53 in complete remission group to chemotherapy was lower than that of progressive disease group (p=0.047, p=0.049). In multivariate analysis, the clinical stage alone showed significance on overall survival (p=0.049). In conclusion, cyclin B1 and cdc2 appeared to be involved in the genesis or progression of malignant lymphoma and cdc2 can be a useful marker for response to chemotherapy.
